| 1 |
32886218 | Improved Erythrocyte Deformability Induced by Sodium-Glucose Cotransporter 2 Inhibitors in Type 2 Diabetic Patients. | 2022 Feb |
1 |
| 2 |
35005849 | Risk of genital and urinary tract infections associated with SGLT-2 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes mellitus: A retrospective cohort study in Korea. | 2022 Feb |
1 |
| 3 |
35120085 | GLP-1 receptor agonists and cardiovascular outcomes in patients with type 2 diabetes: Clinical evidence and best practice. | 2022 Feb 1 |
1 |
| 4 |
35212193 | Characterization, management, and risk factors of hyperglycemia during PI3K or AKT inhibitor treatment. | 2022 Apr |
1 |
| 5 |
31550992 | A Pilot Study Embedding Clinical Pharmacists Within an Interprofessional Nephrology Clinic for the Initiation and Monitoring of Empagliflozin in Diabetic Kidney Disease. | 2021 Jun |
2 |
| 6 |
32067559 | A Review of the Renoprotective Effects of Novel Antidiabetic Agents. | 2021 Feb |
1 |
| 7 |
32879144 | Insulin resistant diabetes mellitus in SHORT syndrome: case report and literature review. | 2021 Jan 28 |
2 |
| 8 |
32979231 | Efficacy and safety of a sodium-glucose co-transporter-2 inhibitor versus placebo as an add-on therapy for people with type 2 diabetes inadequately treated with metformin and a dipeptidyl peptidase-4 inhibitor: a systematic review and meta-analysis of randomised controlled trials. | 2021 Feb |
2 |
| 9 |
33043620 | Sodium-glucose co-transporter-2 inhibitors with and without metformin: A meta-analysis of cardiovascular, kidney and mortality outcomes. | 2021 Feb |
2 |
| 10 |
33120439 | Cardiovascular Safety of Sodium Glucose Cotransporter 2 Inhibitors as Add-on to Metformin Monotherapy in Patients with Type 2 Diabetes Mellitus. | 2021 Jul |
4 |
| 11 |
33181201 | Does background metformin therapy influence the cardiovascular outcomes with SGLT-2 inhibitors in type 2 diabetes? | 2021 Feb |
1 |
| 12 |
33189895 | Could metformin modulate cardiovascular outcomes differently with DPP-4 inhibitors compared with SGLT2 inhibitors? | 2021 Jul |
1 |
| 13 |
33218786 | Changing Fields-Diabetes Medications Invading the Cardiovascular Space. | 2021 Mar |
1 |
| 14 |
33311577 | Effects of SGLT2 inhibitors on eGFR in type 2 diabetic patients-the role of antidiabetic and antihypertensive medications. | 2021 May |
4 |
| 15 |
33420333 | Cardiovascular safety and efficacy of metformin-SGLT2i versus metformin-sulfonylureas in type 2 diabetes: systematic review and meta-analysis of randomized controlled trials. | 2021 Jan 8 |
2 |
| 16 |
33507658 | [News in Diabetology 2020]. | 2021 Jan 27 |
1 |
| 17 |
33606884 | Novel antidiabetic drugs and risk of cardiovascular events in patients without baseline metformin use: a meta-analysis. | 2021 Mar 23 |
2 |
| 18 |
33747548 | Cardiovascular Outcomes in Trials of New Antidiabetic Drug Classes. | 2021 Mar |
1 |
| 19 |
33856655 | The Cost-Effectiveness of Empagliflozin Versus Liraglutide Treatment in People with Type 2 Diabetes and Established Cardiovascular Disease. | 2021 May |
1 |
| 20 |
33857309 | SGLT2 Inhibitors as Calorie Restriction Mimetics: Insights on Longevity Pathways and Age-Related Diseases. | 2021 Aug 1 |
1 |
| 21 |
33880815 | Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for diabetes after solid organ transplantation. | 2021 Aug |
2 |
| 22 |
33881795 | Ambulatory noninsulin treatment of type 2 diabetes mellitus in the United States, 2015 to 2019. | 2021 Aug |
3 |
| 23 |
33973870 | The different hypoglycemic effects between East Asian and non-Asian type 2 diabetes patients when treated with SGLT-2 inhibitors as an add-on treatment for metformin: a systematic review and meta-analysis of randomized controlled trials. | 2021 May 11 |
3 |
| 24 |
33975892 | SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline. | 2021 May 11 |
1 |
| 25 |
34163481 | Metformin, Macrophage Dysfunction and Atherosclerosis. | 2021 |
2 |
| 26 |
34180939 | Comparative Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors vs Sulfonylureas in Patients With Type 2 Diabetes. | 2021 Aug 1 |
3 |
| 27 |
34247911 | Comparing cardiovascular benefits between GLP-1 receptor agonists and SGLT2 inhibitors as an add-on to metformin among patients with type 2 diabetes: A retrospective cohort study. | 2021 Sep |
2 |
| 28 |
34440108 | Metformin Therapy Effects on the Expression of Sodium-Glucose Cotransporter 2, Leptin, and SIRT6 Levels in Pericoronary Fat Excised from Pre-Diabetic Patients with Acute Myocardial Infarction. | 2021 Jul 28 |
3 |
| 29 |
34866061 | The use of SGLT2 inhibitors in achieving glycaemic control in maturity-onset diabetes of the young type 3. | 2021 Dec 1 |
1 |
| 30 |
31407866 | Effects of sodium-glucose cotransporter-2 inhibitors on the cardiovascular and renal complications of type 2 diabetes. | 2020 Jan |
1 |
| 31 |
31694774 | Efficacy and safety of metformin and sodium-glucose co-transporter-2 inhibitors in adults with type1 diabetes: A systematic review and network meta-analysis. | 2020 Jan - Feb |
1 |
| 32 |
31778746 | The right place for metformin today. | 2020 Jan |
1 |
| 33 |
31791665 | The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial. | 2020 Jan |
1 |
| 34 |
32061625 | Does Metformin Interfere With the Cardiovascular Benefits of SGLT2 Inhibitors? Questions About Its Role as the Cornerstone of Diabetes Treatment. | 2020 Jul |
1 |
| 35 |
32274915 | Metabolic syndrome in children. | 2020 Aug |
1 |
| 36 |
32331584 | Corrigendum to "van Bommel EJM, Muskiet MHA, van Baar MJB, et al. The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial." Kidney Int. 2020;97:202-212. | 2020 May |
1 |
| 37 |
32437914 | Glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors as add-on therapy for patients with type 2 diabetes? A systematic review and meta-analysis of surrogate metabolic endpoints. | 2020 Sep |
1 |
| 38 |
32598218 | Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis. | 2020 Aug 18 |
1 |
| 39 |
32700188 | Long-Term Cost-Effectiveness Analyses of Empagliflozin Versus Oral Semaglutide, in Addition to Metformin, for the Treatment of Type 2 Diabetes in the UK. | 2020 Sep |
2 |
| 40 |
32821142 | SGLT2 Inhibitors as Add-On Therapy to Metformin for People with Type 2 Diabetes: A Review of Placebo-Controlled Trials in Asian versus Non-Asian Patients. | 2020 |
1 |
| 41 |
33061964 | Comparing the Efficacy and Safety of Glucagon-Like Peptide 1 Receptor Agonists with Sodium-Glucose Cotransporter 2 Inhibitors for Obese Type 2 Diabetes Patients Uncontrolled on Metformin: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. | 2020 |
1 |
| 42 |
33235419 | Effects of SGLT2 Inhibitors as an Add-on Therapy to Metformin on Electrocardiographic Indices of Ventricular Repolarization. | 2020 Nov |
2 |
| 43 |
30502742 | Impact of currently used anti-diabetic drugs on myoendothelial communication. | 2019 Apr |
1 |
| 44 |
30565386 | Cost-effectiveness of intensification with sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes on metformin and sitagliptin vs direct intensification with insulin in the United Kingdom. | 2019 Apr |
2 |
| 45 |
30639796 | SGLT2 inhibitors and metformin: Dual antihyperglycemic therapy and the risk of metabolic acidosis in type 2 diabetes. | 2019 Mar 5 |
1 |
| 46 |
30697897 | Sodium-glucose co-transporter-2 inhibitor use and risk of lower-extremity amputation: Evolving questions, evolving answers. | 2019 May |
1 |
| 47 |
30724637 | Fixed-dose combination of ertugliflozin and metformin hydrochloride for the treatment of type 2 diabetes. | 2019 Mar |
3 |
| 48 |
30767126 | Cardiovascular Protection with Anti-hyperglycemic Agents. | 2019 Jun |
1 |
| 49 |
30835599 | An evaluation of the efficacy and safety of Tofogliflozin for the treatment of type II diabetes. | 2019 May |
1 |
| 50 |
30930073 | Minimizing Hyperglycemia-Induced Vascular Endothelial Dysfunction by Inhibiting Endothelial Sodium-Glucose Cotransporter 2 and Attenuating Oxidative Stress: Implications for Treating Individuals With Type 2 Diabetes. | 2019 Oct |
1 |